(October 5th 2015) Crossbeta Biosciences and Servier today announced their collaboration in several research projects involving the use of Crossbeta’s technology for generating stable oligomers. Crossbeta and Servier will jointly develop multiple oligomer types that will be used by Servier for its preclinical research programs in CNS. Read the full press release (pdf)
(July 2015) Crossbeta completes financing round and secures Innovation Grant. Crossbeta Biosciences today announced that it has completed a round of internal financing. In addition, the company secured another Innovation Grant from the Dutch government agency RVO for the further development of Crossbeta’s platform technology and stable oligomers in the field of Alzheimer’s, Parkinson’s, ALS and Huntington’s disease. Read the full release (pdf)
Stabilizing oligomers and targeting toxic oligomers is the basis for Crossbeta's oligomer drug discovery platforms which are accessible for partnering in therapeutic areas such as Alzheimer's, Parkinson's, Huntington and Diabetes Type 2.
In our Alzheimer program we have recently completed a high throughput screening campaign with 100,000 compounds resulting in the selection of 5 hit classes with >50% neutralizing effect on oligomer-induced neurotoxicity.
Stable oligomers can also be used as reference in biomarker assays.